Please use the search below. See our frequently asked questions regarding clinical trials.
Showing 1 - 10 of 196
3300 Gallows Road
Falls Church, VA 22042
Since lubiprostone has been shown to increase the frequency of spontaneous bowel movements (SBMs) in both adults and children, further evaluation in well controlled studies in children is needed to demonstrate use in a paediatric population. Study requires use of an electronic diary nightly, 6 visits and 5 blood draws.
One trial will test the primary hypothesis that intensive medical management differs from the combination of CEA and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.
One trial will test the primary hypothesis that intensive medical management differs from the combination of CAS and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.
In both trials, the primary endpoint is stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter at the 4-year time point of follow-up.
Showing 1 - 10 of 196
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaNeuroblastoma Classification Biology Studies
Neuroblastoma Classification Biology Studieshttps://inova.org/clinical-trials/neuroblastoma-classification-biology-studies
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
Inova Children's Hospital3300 Gallows Road
Falls Church, VA 22042
A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma SpecimensDCM Precision Medicine Study
The purpose of this study is to identify gene changes that cause DCM and gene differences that influence the development and severity of DCM. These genetic studies may identify a change in a gene that has already been linked with DCM, a change in a gene not previously associated with DCM, or these studies may identify a gene or genes that affect the development and severity of the DCM. With this knowledge we hope to have a better understanding of how genes and gene changes cause DCM.https://inova.org/clinical-trials/dcm-precision-medicine-study
HARMONY - A Trial to Evaluate the Safety and Efficacy of Amitiza (Lubiprostone) in Children with Constipation
The goal of this study is to evaluate the safety and efficacy of Amitiza (lubiprostone) in children with constipation. Even though traditional treatment of functional constipation in children is available and safe, for many patients it does not provide a satisfying improvement, prompting interest in other therapeutic strategies.Since lubiprostone has been shown to increase the frequency of spontaneous bowel movements (SBMs) in both adults and children, further evaluation in well controlled studies in children is needed to demonstrate use in a paediatric population. Study requires use of an electronic diary nightly, 6 visits and 5 blood draws.
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)
There are two equally important primary hypotheses, which will be tested in two independent parallel, randomized clinical trials.One trial will test the primary hypothesis that intensive medical management differs from the combination of CEA and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.
One trial will test the primary hypothesis that intensive medical management differs from the combination of CAS and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.
In both trials, the primary endpoint is stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter at the 4-year time point of follow-up.